Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 7/20 | 0.38 |
| ▸ | CA1 | P00915 | 6/20 | 0.33 |
| ▸ | MMP1 | P03956 | 2/20 | 0.33 |
| ▸ | MMP2 | P08253 | 2/20 | 0.33 |
| ▸ | MMP9 | P14780 | 2/20 | 0.33 |
| ▸ | MMP8 | P22894 | 2/20 | 0.33 |
| ▸ | MMP13 | P45452 | 2/20 | 0.33 |
| ▸ | F2 | P00734 | 3/20 | 0.31 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.31 |
| ▸ | PRSS2 | P07478 | 3/20 | 0.31 |
| ▸ | PRSS3 | P35030 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15466102 | 0.80 | CA2 (0.34) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL21801551 | 0.79 | — | — | |
| SCHEMBL444566 | 0.76 | CA2 (0.44) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL27868365 | 0.75 | CA2 (0.42) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL13160703 | 0.71 | CA2 (0.35) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL4454952 | 0.68 | F2 (0.46) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL167861 | 0.67 | CA2 (0.48) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL444398 | 0.67 | CA2 (0.41) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL444397 | 0.67 | CA2 (0.41) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL24938906 | 0.66 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260062412-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING MYT1 INHIBITORY ACTIVITY | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2026-03-05 | — | — | US | disclosed |
| EP-4647424-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING MYT1 INHIBITORY ACTIVITY | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-11-12 | — | — | EP | disclosed |
| WO-2024181437-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING MYT1 INHIBITORY ACTIVITY | 中外製薬株式会社 | 2024-09-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260062412-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING MYT1 INHIBITORY ACTIVITY | MYT1, NTMT1, MYL6 | CA2 258/4885CA1 1098/4885MMP1 2559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.